We analyzed the performance characteristics of the qualitative AMPLICOR CMV
Test (Roche Molecular Systems, Pleasanton, Calif,) and quantitative COBAS
AMPLICOR CMV MONITOR Test (Roche Molecular Systems) assays and compared the
performance of the AMPLICOR quantitative assay with an in-house-developed
cytomegalovirus (CMV) DNA PCR assay. The quantitative AMPLICOR assay was fo
und to be more sensitive than the qualitative AMPLICOR assay. The quantitat
ive AMPLICOR assay has a lower limit of sensitivity of 400 CMV DNA copies/m
l of plasma and is linear to 50,000 CMV DNA copies/ml of plasma, Compared t
o the in-house PCR assay, the AMPLICOR quantitative assay gave lower viral
load values at all concentrations tested, but the difference between the tw
o assays was not consistent across the entire dynamic range of the AMPLICOR
quantitative assay, At the lower end of the assay, the viral load values o
btained with the in-house PCR assay were three- to fivefold (0.5 to 0.7 log
units) higher than those measured with the AMPLICOR assay. At higher input
concentrations, the differences between the two assays approached 10-fold,
This direct comparison of the in-house assay and the quantitative AMPLICOR
assay provides the ability to compare previously published in-house data w
ith an assay widely available for future research and clinical monitoring o
f patients with CMV infections.